ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John Yu, MD, Founder and Chief Scientific Officer of ImmunoCellular, will present a corporate overview and business update at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 27, 2013 at 2:30 p.m. ET at the Millennium Broadway Hotel in New York City. To access the live audio webcast of the BioCentury NewsMakers presentation, please log on through a link located in the Investors section of ImmunoCellular’s website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event. About ImmunoCellular Therapeutics, Ltd. ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.